- Home
- AZI vs SKYE Comparison
AZI vs SKYE Comparison
Compare AZI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AZI | SKYE |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 44.9M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | AZI | SKYE |
|---|---|---|
| Price | $0.46 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.75 |
| AVG Volume (30 Days) | ★ 4.7M | 296.3K |
| Earning Date | 02-12-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.90 | N/A |
| 52 Week Low | $0.42 | $0.68 |
| 52 Week High | $69.00 | $5.75 |
Technical Indicators
Market Signals| Indicator | AZI | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 26.66 | 34.34 |
| Support Level | $1.96 | $0.69 |
| Resistance Level | $1.79 | $0.75 |
| Average True Range (ATR) | 0.36 | 0.08 |
| MACD | -0.24 | -0.02 |
| Stochastic Oscillator | 0.44 | 11.65 |
Price Performance
Historical ComparisonAbout AZI Autozi Internet Technology (Global) Ltd. Class A Ordinary Shares
Autozi Internet Technology (Global) Ltd provides high-quality, affordable, and professional one-stop automotive products and services through online and offline channels in China. Leveraging its online supply chain cloud platform, SaaS platforms, and the network of MBS stores, It has established an ecosystem of lifecycle automotive services by connecting automotive manufacturers, auto parts manufacturers, and insurance companies with MBS stores and various automotive owners. Its business segments include new car sales, auto parts and auto accessories sales, and automotive insurance-related services. The majority of revenue is from the new car sales segment, and auto parts & auto accessories sales.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.